 BASKING RIDGE, N.J., Jan. 25, 2021 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has closed on its previously announced sale of an aggregate of 12,500,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of common stock to several institutional and accredited investors, at a purchase price of 2.00 per share and associated warrant, in a private placement priced at-the-market under Nasdaq rules. 